ERROR: Macro njDefaultArticleHeader is missing!

Grapevine

EDA’s emergency management

Back to Top Comments Email Print

Latest News

Morals Village Hot Pot leases at Rutgers Plaza

By Mario Marroquin
April 28, 2017 12:12 PM

North Plainfield-based Levin Management Corp. recently announced it has completed a 4,000-square-foot lease and is adding Morals Village Hot Pot to Rutgers Plaza in Franklin Township. CONTINUE READING

Atlantic Stewardship Bank plans new branch location in Morris County

By April 28, 2017 11:58 AM

Midland Park-based Atlantic Stewardship Bank recently announced it is opening a new branch in North Jersey. CONTINUE READING

advertisement

Marcus & Millichap complete $2.5M sale in Orange

By Mario Marroquin
April 28, 2017 11:47 AM

CONTINUE READING

Innophos names SVP for manufacturing, engineering, environmental health & safety

By Eric Strauss
April 27, 2017 12:31 PM

Innophos Holdings Inc., the Cranbury-based maker of specialty ingredient solutions, said it has named a new senior vice president of manufacturing, engineering and environmental health & safety, it announced Thursday. CONTINUE READING

NAI Hanson sells lot in West Caldwell

By Mario Marroquin
April 27, 2017 01:08 PM

Commercial brokerage NAI James E. Hanson recently announced it has brokered the sale of a 0.8-acre lot in West Caldwell between Lourenco Service Center and Manzo-Doren Organization of West Caldwell. CONTINUE READING

Software solutions firm hires CFO

By Eric Strauss
April 26, 2017 11:35 AM

Princeton-based business software solutions provider AMERI Holdings Inc. has named a new chief financial officer, it said Tuesday. CONTINUE READING

Marcus & Millichap completes sale in Elizabeth

By Mario Marroquin
April 26, 2017 12:06 PM

Commercial real estate firm Marcus & Millichap recently announced the completion of a $1.4 million property sale in Elizabeth through a 1031 exchange. Michael Lombardi, first vice president at Marcus & Millichap New Jersey’s office, represented private investors in the sale and purchase of the property. CONTINUE READING

advertisement

With a long-delayed incentives overhaul on its way to becoming law, the state is rolling out emergency guidelines to open itself for business under the new programs, sources said.

One person said the Economic Development Authority could start accepting applications for the new incentives as soon as October, assuming Chris Christie signs the Economic Opportunity Act into law as expected. To do so, a source said, the agency is expected to adopt temporary regulations and formalize them at a later time.

The move would allow many firms and developers to break their holding patterns of the past several months, as they waited on lawmakers and administration officials who wrangled over the high-stakes bill. But the lengthy delay also has allowed the EDA to prepare for a wave of applications, a source said.

The person said the normal process of adopting regulations “just takes time, and there would be a significant void if they went with that process,” because big-ticket incentives like the Urban Transit Hub and Grow New Jersey tax credits are running on empty.

Sale of Ortho sensible for J&J

Speculation has resurfaced that Johnson & Johnson is looking sell its blood-test division, Ortho Clinical Diagnostics, by the end of the year.

Sources following the pharma industry say such a move make sense because blood tests tend to be a low-tech, lower-margin business, offering less returns than newer categories of tests, such as molecular diagnostics, which examine genes.

“This is not a high-margin business,” one source said of blood tests. “It does not add to return on investment. Why do low ROI? It makes no sense. Twenty years ago, you could, because no one else was doing it. But now smaller companies are doing it at lower cost.”

The Wall Street Journal has reported J&J is talking to other health care companies and private equity investors. The New Brunswick-based company isn't talking now, though CEO Alex Gorsky in January said the company was considering divesting the asset as it  focuses more on higher growth drivers. 

Gorsky has said the blood-testing unit may be a better fit as part of another company, or as a standalone company.

Grapevine reports on the behind-the-scenes buzz in the business community. Contact Editor Tom Bergeron at tomb@njbiz.com.

Share This Story On:

EDA’s emergency management

Back to Top Comments Email Print

Latest News

advertisement

With a long-delayed incentives overhaul on its way to becoming law, the state is rolling out emergency guidelines to open itself for business under the new programs, sources said.

One person said the Economic Development Authority could start accepting applications for the new incentives as soon as October, assuming Chris Christie signs the Economic Opportunity Act into law as expected. To do so, a source said, the agency is expected to adopt temporary regulations and formalize them at a later time.

The move would allow many firms and developers to break their holding patterns of the past several months, as they waited on lawmakers and administration officials who wrangled over the high-stakes bill. But the lengthy delay also has allowed the EDA to prepare for a wave of applications, a source said.

The person said the normal process of adopting regulations “just takes time, and there would be a significant void if they went with that process,” because big-ticket incentives like the Urban Transit Hub and Grow New Jersey tax credits are running on empty.

Sale of Ortho sensible for J&J

Speculation has resurfaced that Johnson & Johnson is looking sell its blood-test division, Ortho Clinical Diagnostics, by the end of the year.

Sources following the pharma industry say such a move make sense because blood tests tend to be a low-tech, lower-margin business, offering less returns than newer categories of tests, such as molecular diagnostics, which examine genes.

“This is not a high-margin business,” one source said of blood tests. “It does not add to return on investment. Why do low ROI? It makes no sense. Twenty years ago, you could, because no one else was doing it. But now smaller companies are doing it at lower cost.”

The Wall Street Journal has reported J&J is talking to other health care companies and private equity investors. The New Brunswick-based company isn't talking now, though CEO Alex Gorsky in January said the company was considering divesting the asset as it  focuses more on higher growth drivers. 

Gorsky has said the blood-testing unit may be a better fit as part of another company, or as a standalone company.

Grapevine reports on the behind-the-scenes buzz in the business community. Contact Editor Tom Bergeron at tomb@njbiz.com.

Share This Story On:
advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy
advertisement
ERROR: Macro defaultSidebar is missing!
ERROR: Macro footer_top is missing!
Back to Top